{"id":36253,"date":"2025-06-30T15:12:06","date_gmt":"2025-06-30T07:12:06","guid":{"rendered":"https:\/\/flcube.com\/?p=36253"},"modified":"2025-06-30T15:12:07","modified_gmt":"2025-06-30T07:12:07","slug":"pfizers-emblaveo-approved-by-chinas-nmpa-for-complex-infections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36253","title":{"rendered":"Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections"},"content":{"rendered":"\n

US giant Pfizer Inc., (NYSE: PFE<\/a>) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.<\/p>\n\n\n\n

Drug Profile<\/strong>
Emblaveo is the first \u03b2-lactam\/\u03b2-lactamase inhibitor combination to cover all types of carbapenemase enzymes. The fixed-dose combination design provides broad-spectrum enzyme inhibition, including KPC carbapenemases, OXA-48 carbapenemases, and Metallo-\u03b2-lactamases (MBLs). This addresses a key limitation of existing \u03b2-lactamase inhibitors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s…<\/p>\n","protected":false},"author":1,"featured_media":36254,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[863,309,15],"class_list":["post-36253","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-pfe","tag-pfizer","tag-product-approvals"],"yoast_head":"\nPfizer's Emblaveo Approved by China's NMPA for Complex Infections - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36253\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections\" \/>\n<meta property=\"og:description\" content=\"US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36253\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-30T07:12:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-30T07:12:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections\",\"datePublished\":\"2025-06-30T07:12:06+00:00\",\"dateModified\":\"2025-06-30T07:12:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253\"},\"wordCount\":118,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3003.webp\",\"keywords\":[\"NYSE: PFE\",\"Pfizer\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36253#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36253\",\"name\":\"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3003.webp\",\"datePublished\":\"2025-06-30T07:12:06+00:00\",\"dateModified\":\"2025-06-30T07:12:07+00:00\",\"description\":\"US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36253\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3003.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36253#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections - Insight, China's Pharmaceutical Industry","description":"US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36253","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections","og_description":"US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.","og_url":"https:\/\/flcube.com\/?p=36253","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-30T07:12:06+00:00","article_modified_time":"2025-06-30T07:12:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36253#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36253"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections","datePublished":"2025-06-30T07:12:06+00:00","dateModified":"2025-06-30T07:12:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36253"},"wordCount":118,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36253#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp","keywords":["NYSE: PFE","Pfizer","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36253#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36253","url":"https:\/\/flcube.com\/?p=36253","name":"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36253#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36253#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp","datePublished":"2025-06-30T07:12:06+00:00","dateModified":"2025-06-30T07:12:07+00:00","description":"US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36253#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36253"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36253#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp","width":1080,"height":608,"caption":"Pfizer's Emblaveo Approved by China's NMPA for Complex Infections"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36253#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36253"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36253\/revisions"}],"predecessor-version":[{"id":36255,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36253\/revisions\/36255"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36254"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}